|
|
|
|
|
|
| 1980 | 8 | Sup.1 | FDA Bureau of Drugs Clinical Guidelines | FDA |
| 1983 | 11 | Sup.2 | The Controller Committee | |
| 1985 | 13 | Sup.3 | Recent Topics on Clinical Trials | The Controller Committee |
| 1987 | 15 | Sup.4 | The Controller Committee | |
| 1990 | 18 | Sup.5 | FDA Bureau of Drugs Clinical Guidelines Ⅱ | FDA |
| 1992 | 20 | Sup.6 | Clinical and Statistical Aspects of Drug Approval | The Controller Committee |
| 1993 | 21 | Sup.7 | "Drug Approval and Clinical Trials" －Practical Problems for Clinical Investigators and Researchers－ |
The Controller Committee |
| 1994 | 22 | Sup.8 | FDA (translator: Keiji Ueda, Yoshihito Omori, The Controller Committee) | |
| 1995 | 23 | Sup.9 | Recent Topics on Switched OTC in USA | FDA (translator: Naokata Shimizu) |
| 1996 | 24 | Sup.10 | Guideline for Good Clinical Practice ICH Harmonised Tripartite Guideline | The Controller Committee |
| 1997 | 24 | Sup.11 | The Controller Committee | |
| 1997 | 25 | Sup.12 | The Controller Committee | |
| 1999 | 26 | Sup.13 | Evidence of Off-Label Use of Drug | Kiichiro Tsutani, Naokata Shimizu |
| 2000 | 27 | Sup.14 | World wide view on development and evaluation of switched and direct OTC | |
| 2001 | 28 | Sup.15 | Bridging Strategies | Ed. by Stephen W. Lagakos & Masahiro Takeuchi |
| 2001 | 29 | Sup.16 | Clinical Evaluation of OTC Drugs and Traditional Drugs | Ed. by Naokata Shimizu, Kiichiro Tsutani |
| 2002 | 29 | Sup.17 | Bridging Strategies and Pharmacogenomics | Ed. by Masahiro Takeuchi & Stephen W. Lagakos |
| 2003 | 30 | Sup.18 | Ed. by Naokata Shimizu, Syozo Koshikawa, Takeo Nomura, Gotaro Toda |
|
| 2003 | 30 | Sup.19 | Simultaneous, Worldwide Development Strategies | Ed. by Masahiro Takeuchi & Stephen W. Lagakos |
| 2004 | 31 | Sup.20 | Forefront of New Drug Development Strategies | Ed. by Masahiro Takeuchi & Stephen W. Lagakos |
| 2004 | 32 | Sup.21 | Scientific and ethical evaluation of regenerative medicine Focus on bone marrow and fetal stem cell clinical research |
|
| 2005 | 32 | Sup.22 | Global Development Strategies of New Drugs | Ed. by Masahiro Takeuchi & Stephen W. Lagakos |
| 2006 | 33 | Sup.23 | Development, Evaluation and Approval of New Drugs | Ed. by Masahiro Takeuchi & Stephen W. Lagakos |
| 2006 | 34 | Sup.24 | What is the TGN 1412 case ? | |
| 2007 | 35 | Sup.25 | Japan's Critical Path Opportunities | Ed. by Masahiro Takeuchi & Stephen W. Lagakos |
| 2009 | 36 | Sup.26 | Clinical science: Principles and practice－Science, law and humanity－ | |
| 2009 | 37 | Sup.27 | Learning from Experience and New Challenges for the Future | Ed. by Masahiro Takeuchi & Stephen W. Lagakos |
| 2010 | 37 | Sup.28 | Significance of Asian Studies in Simultaneous Global Clinical Trials | Ed. by Masahiro Takeuchi & Stephen W. Lagakos |
| 2011 | 39 | Sup.29 | Innovative Strategies for Future Objectives | Ed. by Masahiro Takeuchi & Lee Jen Wei |
| 2012 | 40 | Sup.30 | Innovative Strategies for Enhancing Regional Drug Development as a Global Drug Development | Ed. by Masahiro Takeuchi & Lee Jen Wei |
| 2012 | 40 | Sup.31 | Public Debriefing Session 2011 | |
| 2014 | 42 | Sup.32 | Next Steps and Actions as one of the Leading Countries | Ed. by Masahiro Takeuchi & Lee Jen Wei |
| 2014 | 42 | Sup.33 | Public Debriefing Session 2013 | |
| 2015 | 43 | Sup.34 | Moving beyond the Comfort Zone | Ed. by Masahiro Takeuchi & Lee Jen Wei |
| 2015 | 43 | Sup.35 | Public Debriefing Session 2014 | |
| 2019 | 47 | Sup.36 | Achievements of AMED and exponential research and development in Japan / The Steps to Disease Control: University’s mission to establish an R&D ecosystem |
|
| 2021 | 48 | Sup.37 | The real status of Japan’s “2040 issue”: The role and mission of TRI / Road to Learning Health Society |
|
| 2021 | 49 | Sup.38 | COVID-19 and bioethics Part 3: Pandemic and research ethics－Democracy, placebo and post-trial access |